Self-Delivery of Metal-Coordinated Anti-Angiogenic Nanodrug

with GSH Depleting Ability for Synergistic Chemo-Phototherapy

Fukai Zhu, ^{a, b, c, d, f} Cailin Huang, ^{c, f} YanLing Lin, ^{c, f} Yang Li ^{c, f, *} Ruiqin Tu, ^{d, e} Weihong Lu, ^{a, d, *}

^a Department of Gynecology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.

^b Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian 363000, China.

^c CAS Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, China.

^d Xiamen Clinical Research Center for Cancer Therapy, Xiamen, 361015, China

^e Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

^f Department of Translational Medicine & Xiamen Key Laboratory of Rare Earth Photoelectric Functional Materials, Xiamen Institute of Rare-Earth Materials, Haixi Institute, Chinese Academy of Sciences, Xiamen 361021, China.

*Corresponding authors:

li.yang@fjirsm.ac.cn; lu.weihong@zsxmhospital.com



Figure S1. Physiological stability of ICCR dispersed in saline, PBS, DMEM and DMEM containing 10% serum.



Figure S2. TEM images of ICC nanodrug treated with GSH (I, originated from Figure 2H), weak acidity (pH 6.5) (II), relatively strong acidity (pH 5.0) for 6 h.



Figure S3. Temperature change of ICCR nanodrug with laser irradiation cycles.



Figure S4. GSH consumption capacity of ICCR nanodrug determined by UV-vis spectra of Ellman's reagents (5, 5'-dithiobis-(2-nitrobenzoic acid) (DTNB) in GSH pre-incubated with ICCR.



Figure S5. *In vitro* ROS generation ability of ICCR *via* methylene blue (MB) degradation assay.



Figure S6. Immunofluorescent staining of different groups for vascular endothelial growth factor (VEGF).